Suppr超能文献

接受富血小板血浆或骨髓抽吸浓缩注射治疗的膝骨关节炎患者比接受透明质酸治疗的患者有更好的疗效:系统评价和荟萃分析。

Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis.

机构信息

University of Colorado School of Medicine, Aurora, Colorado, U.S.A.

University of Colorado Boulder, Boulder, Colorado, U.S.A.

出版信息

Arthroscopy. 2023 Jul;39(7):1714-1734. doi: 10.1016/j.arthro.2023.03.001. Epub 2023 Mar 11.

Abstract

PURPOSE

To systematically review the literature to compare the efficacy and safety of platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and hyaluronic acid (HA) injections for the treatment of knee osteoarthritis (OA).

METHODS

A systematic review was performed by searching PubMed, the Cochrane Library, and Embase to identify Level I studies that compared the clinical efficacy of at least 2 of the following 3 injection therapies: PRP, BMAC, and HA for knee OA. The search phrase used was knee AND osteoarthritis AND randomized AND ("platelet rich plasma" OR "bone marrow aspirate" OR "hyaluronic acid"). Patients were primarily assessed based on patient-reported outcome scores (PROs) including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), visual analog scale (VAS) for pain, and Subjective International Knee Documentation Committee (IKDC) score.

RESULTS

Twenty-seven studies (all Level I) met inclusion criteria, including 1,042 patients undergoing intra-articular injection(s) with PRP (mean age 57.7 years, mean follow-up 13.5 months), 226 patients with BMAC (mean age 57.0 years, mean follow-up 17.5 months), and 1,128 patients with HA (mean age 59.0 years, mean follow-up 14.4 months). Nonnetwork meta-analyses demonstrated significantly better postinjection WOMAC (P < .001), VAS (P < .01), and Subjective IKDC scores (P < .001) in patients who received PRP compared with patients who received HA. Similarly, network meta-analyses demonstrated significantly better postinjection WOMAC (P < .001), VAS (P = .03), and Subjective IKDC (P < .001) scores in patients who received BMAC compared with patients who received HA. There were no significant differences in postinjection outcome scores when comparing PRP with BMAC.

CONCLUSIONS

Patients undergoing treatment for knee OA with PRP or BMAC can be expected to experience improved clinical outcomes when compared with patients who receive HA.

LEVEL OF EVIDENCE

Level I, meta-analysis of Level I studies.

摘要

目的

系统回顾文献,比较富血小板血浆(PRP)、骨髓抽吸浓缩物(BMAC)和透明质酸(HA)注射治疗膝骨关节炎(OA)的疗效和安全性。

方法

通过检索 PubMed、Cochrane 图书馆和 Embase,查找至少比较以下 3 种注射疗法中的 2 种临床疗效的 I 级研究:PRP、BMAC 和 HA 治疗膝 OA。使用的搜索词是膝关节和骨关节炎和随机和(“富含血小板的血浆”或“骨髓抽吸”或“透明质酸”)。患者主要根据患者报告的结果评分(PROs)进行评估,包括西安大略和麦克马斯特大学骨关节炎指数(WOMAC)、疼痛视觉模拟量表(VAS)和主观国际膝关节文献委员会(IKDC)评分。

结果

27 项研究(均为 I 级)符合纳入标准,包括 1042 例接受关节内注射 PRP(平均年龄 57.7 岁,平均随访 13.5 个月)、226 例接受 BMAC(平均年龄 57.0 岁,平均随访 17.5 个月)和 1128 例接受 HA(平均年龄 59.0 岁,平均随访 14.4 个月)的患者。非网络荟萃分析显示,与接受 HA 治疗的患者相比,接受 PRP 治疗的患者注射后 WOMAC(P <.001)、VAS(P <.01)和主观 IKDC 评分(P <.001)明显更好。同样,网络荟萃分析显示,与接受 HA 治疗的患者相比,接受 BMAC 治疗的患者注射后 WOMAC(P <.001)、VAS(P =.03)和主观 IKDC(P <.001)评分明显更好。比较 PRP 与 BMAC 时,注射后结局评分无显著差异。

结论

与接受 HA 治疗的患者相比,接受 PRP 或 BMAC 治疗的膝骨关节炎患者可预期获得更好的临床疗效。

证据水平

I 级,I 级研究的荟萃分析。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验